These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 33753342)

  • 1. Finafloxacin Is an Effective Treatment for Inhalational Tularemia and Plague in Mouse Models of Infection.
    Barnes KB; Richards MI; Laws TR; Núñez A; Thwaite JE; Bentley C; Harding SV
    Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33753342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Fluorocycline TP-271 Is Efficacious in Models of Aerosolized Francisella tularensis SCHU S4 Infection in BALB/c Mice and Cynomolgus Macaques.
    Grossman TH; Anderson MS; Christ D; Gooldy M; Henning LN; Heine HS; Kindt MV; Lin W; Siefkas-Patterson K; Radcliff AK; Tam VH; Sutcliffe JA
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Fluoroquinolone Finafloxacin Protects BALB/c Mice Against an Intranasal Infection With
    Barnes KB; Hamblin KA; Richards MI; Laws TR; Vente A; Atkins HS; Harding SV
    Front Microbiol; 2019; 10():904. PubMed ID: 31118924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection Afforded by Fluoroquinolones in Animal Models of Respiratory Infections with Bacillus anthracis, Yersinia pestis, and Francisella tularensis.
    Peterson JW; Moen ST; Healy D; Pawlik JE; Taormina J; Hardcastle J; Thomas JM; Lawrence WS; Ponce C; Chatuev BM; Gnade BT; Foltz SM; Agar SL; Sha J; Klimpel GR; Kirtley ML; Eaves-Pyles T; Chopra AK
    Open Microbiol J; 2010 Jun; 4():34-46. PubMed ID: 21127743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Demonstrating the Protective Efficacy of the Novel Fluoroquinolone Finafloxacin against an Inhalational Exposure to Burkholderia pseudomallei.
    Barnes KB; Hamblin KA; Richards MI; Laws TR; Vente A; Atkins HS; Harding SV
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438936
    [No Abstract]   [Full Text] [Related]  

  • 6. Influence of pH on the activity of finafloxacin against extracellular and intracellular Burkholderia thailandensis, Yersinia pseudotuberculosis and Francisella philomiragia and on its cellular pharmacokinetics in THP-1 monocytes.
    Chalhoub H; Harding SV; Tulkens PM; Van Bambeke F
    Clin Microbiol Infect; 2020 Sep; 26(9):1254.e1-1254.e8. PubMed ID: 31404671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. YopP-expressing variant of Y. pestis activates a potent innate immune response affording cross-protection against yersiniosis and tularemia [corrected].
    Zauberman A; Flashner Y; Levy Y; Vagima Y; Tidhar A; Cohen O; Bar-Haim E; Gur D; Aftalion M; Halperin G; Shafferman A; Mamroud E
    PLoS One; 2013; 8(12):e83560. PubMed ID: 24358292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective, broad spectrum control of virulent bacterial infections using cationic DNA liposome complexes combined with bacterial antigens.
    Ireland R; Olivares-Zavaleta N; Warawa JM; Gherardini FC; Jarrett C; Hinnebusch BJ; Belisle JT; Fairman J; Bosio CM
    PLoS Pathog; 2010 May; 6(5):e1000921. PubMed ID: 20523903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia.
    Jia Q; Bowen R; Dillon BJ; Masleša-Galić S; Chang BT; Kaidi AC; Horwitz MA
    Sci Rep; 2018 May; 8(1):7009. PubMed ID: 29725025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo efficacy of fluoroquinolones against systemic tularaemia infection in mice.
    Piercy T; Steward J; Lever MS; Brooks TJ
    J Antimicrob Chemother; 2005 Dec; 56(6):1069-73. PubMed ID: 16223941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposome encapsulation of ciprofloxacin improves protection against highly virulent Francisella tularensis strain Schu S4.
    Hamblin KA; Armstrong SJ; Barnes KB; Davies C; Wong JP; Blanchard JD; Harding SV; Simpson AJ; Atkins HS
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3053-9. PubMed ID: 24637682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of serotonin and dopamine on growth of Yersinia pestis and Francisella tularensis strains].
    Mishan'kin BN; Dem'ianenko SV; Romanova LV
    Zh Mikrobiol Epidemiol Immunobiol; 2009; (2):93-6. PubMed ID: 19459486
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Steenbergen J; Tanaka SK; Miller LL; Halasohoris SA; Hershfield JR
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of the latest fluoroquinolones against experimental Yersinia pestis.
    Steward J; Lever MS; Russell P; Beedham RJ; Stagg AJ; Taylor RR; Brooks TJ
    Int J Antimicrob Agents; 2004 Dec; 24(6):609-12. PubMed ID: 15555886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of serotonin on immune competent cells of biomodels under the conditions of vaccination against plague and tularemia].
    Kliueva SN; Kravtsov AL; Shchukovskaia TN
    Zh Mikrobiol Epidemiol Immunobiol; 2015; (1):32-8. PubMed ID: 25842950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consequences of delayed ciprofloxacin and doxycycline treatment regimens against Francisella tularensis airway infection.
    Rotem S; Bar-Haim E; Cohen H; Elia U; Ber R; Shafferman A; Cohen O
    Antimicrob Agents Chemother; 2012 Oct; 56(10):5406-8. PubMed ID: 22850512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-exposure immunization against Francisella tularensis membrane proteins augments protective efficacy of gentamicin in a mouse model of pneumonic tularemia.
    Sutherland MD; Goodyear AW; Troyer RM; Chandler JC; Dow SW; Belisle JT
    Vaccine; 2012 Jul; 30(33):4977-82. PubMed ID: 22652404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of murine pneumonic Francisella tularensis infection with gatifloxacin, moxifloxacin or ciprofloxacin.
    Steward J; Piercy T; Lever MS; Simpson AJ; Brooks TJ
    Int J Antimicrob Agents; 2006 May; 27(5):439-43. PubMed ID: 16621457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Explorative Randomized Phase II Clinical Study of the Efficacy and Safety of Finafloxacin versus Ciprofloxacin for Treatment of Complicated Urinary Tract Infections.
    Wagenlehner F; Nowicki M; Bentley C; Lückermann M; Wohlert S; Fischer C; Vente A; Naber K; Dalhoff A
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29339395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Survey of Tularemia and Plague in Small Mammals From Iran.
    Mostafavi E; Ghasemi A; Rohani M; Molaeipoor L; Esmaeili S; Mohammadi Z; Mahmoudi A; Aliabadian M; Johansson A
    Front Cell Infect Microbiol; 2018; 8():215. PubMed ID: 30042927
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.